Abstract: A dosing unit for a machine for producing unit dose articles includes a plurality of nozzles carried by respective movable elements and associated to respective dosing chambers, a plurality of plungers reciprocally movable into respective dosing chambers between respective retracted and advanced positions, and a rotary fluid distributor including at least one stationary inlet and a plurality of movable outlets fluidically connected to the respective dosing chambers.

Abstract: This invention relates to a composition, preferably a demake-up cosmetic composition, comprising: an oily phase dispersed in an aqueous phase, at least one homopolymer of non-superabsorbent acrylic acid that is at least partially neutralized, at least one cross-linked copolymer of (meth)acrylic acid and of C1-C6 alkyl acrylate, at least one polysaccharide gelling agent comprising at least one glucose monomer, and said composition having a pH greater than or equal to 5.5. It also relates to the use of such a composition for the demake-up of keratin materials.

Abstract: The present invention provides an emulsion composition comprising aprepitant for treatment of emesis. Particularly, the invention is a ready-to-use emulsion compositions comprising aprepitant and medium chain triglycerides for administration by intravenous infusion, wherein the emulsion composition is also free of ethanol. Further, the invention also provides processes of preparing such compositions and their use for the prevention and control of acute and delayed chemotherapy-induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.

Abstract: The present invention relates to a process for preparing a mixture of cetylated fatty acids and a system for carrying out said process. Furthermore, the present invention relates to a composition comprising, or alternatively, consisting of said mixture of cetylated fatty acids. Finally, the present invention relates to said composition for use in the treatment and/or prevention of: (i) rheumatoid arthritis of inflammatory and non-inflammatory origin, in particular osteoarthritis; (ii) other inflammatory joint conditions; (iii) psoriasis, lupus, periodontal diseases or cardiovascular or heart diseases; (iv) all post-traumatic osteoarticular pathologies including sports injuries; (v) all degenerative joint pathologies (arthrosis, gonarthrosis, coxarthrosis, etc.), and (vi) inflammatory-traumatic tendon and muscular conditions.

Abstract: The present invention relates to a composition and a method for treating substrates, such as fabrics; in particular a composition that can deliver cleaning and anti-microbial benefits to the fabric thereby delaying laundry. There is a long left need for a composition, which can clean the fabric and deliver anti-microbial benefits without the use of water and detergents. It is therefore an object of the present invention to provide a composition with no surfactants in it which can deliver cleaning and anti-microbial benefits through a single product. It has been found that cleaning and anti-microbial benefits on fabric can be achieved by a solvent mix of a glycol ether, a fatty acid ester and a diol in combination with a bipolar antimicrobial particle in an aqueous solution.

Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to amyloid beta toxicity and/or neuronal death and/or glucose-impaired neuronal metabolism. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease-related disorders, frontotemporal dementia, Parkinson's disease, Lewy body dementia, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on baclofen, acamprosate and at least one medium chain triglyceride.

Abstract: The present invention provides compositions containing efinaconazole, butylated hydroxytoluene, a salt of ethylenediaminetetraacetic acid, and optional citric acid. The compositions exhibit stable color profiles and are useful in the treatment of fungal infections.

Abstract: The invention is directed to a composition comprising a first low-melt wax, a second low-melt wax, a high-melt wax, one or more oil phases, and optionally a flavoring agent.

Abstract: The present invention provides an agent for prophylactic treatment, therapeutic treatment, or prevention of metastasis of giant cell tumor occurring in a bone and soft tissue, chondrosarcoma, or bone sarcoma, a local infusion for artery embolization, and an artificial bone, which comprises a substance having a PPAR?-agonistic activity and/or a PPAR? expression-inducing activity as an active ingredient. The agent for prophylactic treatment, therapeutic treatment, or prevention of metastasis, the local infusion for artery embolization, and the artificial bone of the present invention are a radical therapeutic agent or radical therapeutic material that can cause apoptosis in giant cell tumor occurring in a bone and soft tissue, chondrosarcoma, or bone sarcoma to make the tumor disappear, and can induce differentiation of the tumor into fat cells to make the tumor disappear.

Abstract: The present invention relates to an antimicrobial composition and more particularly an antimicrobial composition for leave-on applications. The present invention discloses an antimicrobial composition comprising; a) 0.01 to 2% by weight of thymol; b) 0.01 to 2% by weight of terpineol; and c) 0.1 to 2% by weight of a cationic phospholipid complex.

Abstract: The present invention provides compositions containing efinaconazole, butylated hydroxytoluene, a salt of ethylenediaminetetraacetic acid, and optional citric acid. The compositions exhibit stable color profiles and are useful in the treatment of fungal infections.

Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Abstract: Compositions including a fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to anemic conditions, are provided, including compositions and methods for treating anemic conditions such as hemolytic anemia and anemia of chronic disease, and other related conditions.

Abstract: The present invention is directed to compositions of green coalescents comprising monoesters obtained from direct or indirect esterification of vegetable oil fatty acids and fusel oil alcohols. The fatty acids used in the present invention have 6 to 22 carbon atoms and can be either saturated or unsaturated.

Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Abstract: The present invention provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate or a derivative thereof, and are administered topically, for example, to treat viral, fungal or bacterial infections.

Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

Abstract: The object of the present invention is the use of compounds designed to inhibit the activity of the enzyme 5?-reductase. This is a novel use of compounds of general formula (I): CH3(—CH?CH)n—R??(I) where n=from 2 to 7, and R is chosen from among: CHO, CH2OH, CH2O—CO—R?, CO—O(?), where R? is chosen from among H, and the alky from C1 to C22, each compound of general formula (I) being used as such or in mixtures with other compounds, as the active principle in a pharmaceutical or cosmetic composition designed to inhibit the action of the enzyme 5?-reductase, and of the pharmaceutical or cosmetic compositions deriving therefrom.

Abstract: The present invention provides compositions containing efinaconazole, butylated hydroxytoluene, a salt of ethylenediaminetetraacetic acid, and optional citric acid. The compositions exhibit stable color profiles and are useful in the treatment of fungal infections.

Abstract: In one aspect, this invention relates to a nematode repellent composition comprising an effective nematode repellent amount of a fatty acid and an anthranilate ester. In another aspect, this invention relates to a method of repelling nematodes employing such composition.

Abstract: Suggested are alkoxylation products of 2-isopropyl-5-methyl-hexan-1-ol in which AO stands for an ethylene oxide, propylene oxide or butylenes oxide unit or their mixtures and n denominates an integer of from 1 to 100.

Abstract: [Problem] To provide a novel antimicrobial agent that has excellent antimicrobial activity and which is prepared from an ester composed of propanediol and a ?-hydroxycarboxylic acid. [Solution] An antimicrobial agent which is prepared from a propanediol mono-?-hydroxycarboxylic acid ester expressed by the following formula (1) or formula (2) (wherein R1 and R2 are both branched or unbranched, and saturated or unsaturated alkyl groups having 5 to 9 carbon atoms).

Abstract: Compositions comprising terpene compounds for the treatment of negative sensory phenomena (NSP). Negative sensory phenomena is characterized by a decreased ability to sense light touch, pin prick, vibration, temperature, pain and/or reduced proprioception. The terpene compounds are preferably aromatic terpene compounds such as geraniol and citronellol and analogs thereof. The terpenes may also be used in combination. The terpenes are derived form plant essential oils or are manufactured synthetically.

Abstract: An exemplary embodiment provides a particulate-free microdermabrasion formulation that includes a emulsifying agent; an ionic salt; a moisturizer; a neutralizer; and water. The formulation is free of acids, abrasive particulates, and enzymes. Further, upon application of the formulation to the skin surface, the formulation forms a thin layer that coats the skin surface and penetrates into pores of the skin. The thin layer sloughs off upon light rubbing, for example by hand or with a soft cloth or wipe, thereby removing dead skin cells and debris from the skin surface to leave a smooth, moisturized newly exposed skin surface.

Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.

Abstract: [Problem] Provision of a composition for external use on skin that is safe to use and has an anti-inflammatory and anti-allergic actions. [Solution] A composition for external use on skin in the treatment of inflammatory disease which comprises dihomo-?-linolenic acid (DGLA) as an active ingredient. The DGLA is preferably contained as a glyceride, a phospholipid, or an alkyl ester. The composition for external use contains DGLA in an amount of 0.1-50 wt %.

Abstract: A personal cleansing composition that increases the deposition and retention of benefit agent containing polyacrylate microcapsules onto hair and/or skin. The personal cleansing composition is based on the combination of anionic charged polyacrylate microcapsules, cationic deposition polymers, detersive surfactant, and a carrier.

Abstract: The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR? modulation such as diabetes.

Abstract: A subject of the present invention is a cosmetic composition of oil-in-water emulsion type comprising: (1) at least one gemini surfactant of formula (I): in which R1 and R3 denote, independently of one another, an alkyl radical having from 1 to 25 carbon atoms; R2 denotes a spacing group consisting of a linear or branched alkylene chain having from 1 to 12 carbon atoms; X and Y denote, independently of one another, a —(C2H4O)a—(C3H6O)bZ group; n ranges from 1 to 10; and -n ranges from 1 to 10; and (2) at least 20% by weight of the total weight of the composition of a fatty phase comprising at least one oil and at least one fatty substance chosen from solid fatty substances and pasty fatty substances; the level of fatty substances chosen from solid fatty substances and pasty fatty substances representing between ? and ? by weight of the fatty phase.

Abstract: Disclosed is an ophthalmic composition containing (A) not less than 50,000 units/100 mL of vitamin A, (B) not less than 0.4 W/V % of a polyoxyethylene polyoxypropylene glycol, and (C) trometamol.

Abstract: Methods of delaying the onset of an infection or preventing an infection caused by a microbial organism in an internal cavity of a subject are provided. Methods of killing or inactivating microorganisms in at least a portion of the urethra of a subject are provided.

Abstract: The present invention relates to a method of lowering cholesterol in a patient in need thereof by administering to said patient a therapeutic effective amount of a compound selected from the group of Dihydroxyacetone phosphate (DHAP); 1-acyl-DHAP; 1-alkyl-DHAP; 1-alkyl-glyceraldehyde-3-phosphate (G3P); 1-alkyl, 2-acyl-G3P; 1-alkyl, 2-acyl-glycerol; 1-alkyl,2-acyl-glycerylphosphatidylethanolamine (GPE), 1-alkyl, diacyl glycerol (sn-1=16:0, sn-2=docosohexaenoic acid (DHA); sn-3=DHA) (sn-1 position has an alkyl ether bond, sn-2 and sn-3 positions have acyl bonds); 1-alkyl diacyl glycerol (sn-1=16:0, sn-2=18:1, sn-3=18:1) (sn-1 position has an alkyl ether bond, sn-2 and sn-3 positions have acyl bonds); triacyl glycerol (sn-1=16:0, sn-2=DHA, sn-3=DHA) (all three positions have acyl bonds); and triacyl glycerol (sn-1=16:0, sn-2=18:1, sn-3=18:1) (all three positions have acyl bonds) and pharmaceutically acceptable salts thereof.

Abstract: It is an object of the present invention to provide a pest control composition capable of exerting a high effect on pests such as spider mites and aphids even at low concentration using a food/food additive with high safety to the human body and the environment. The present inventors have intensively studied to solve the above problem and found that, among polyglycerol fatty acid esters widely used as a food additive, a composition containing a polyglycerol fatty acid ester which has an HLB of 5 or less and is liquid at ordinary temperature and also a nonionic surfactant has a high effect on pests even at low concentration, and that the possibility for pests to develop resistance to the composition is extremely low, and the present invention has been completed.

Abstract: Provided are nutraceutical or dietary supplemental compositions comprising esterified capsaicinoids. The esterified capsaicinoids may converted to the active parent capsaicinoid compound following enzymatic or chemical hydrolysis. In various embodiments, these esterified capsaicinoids have a higher lipophilicity, lipid solubility and result in less irritation to the stomach than the parent capsaicinoid, and hence may be included in certain dietary supplement formulations, including capsules, pills and tablets dietary supplement formulations. The dietary supplement compositions may be used for pain management in mammals in vivo and/or in the treatment of various pathological conditions in humans.

Abstract: The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation.

Abstract: A method of reducing the spread of disease by inhibiting the growth of or eliminating harmful bacteria which are the cause of the disease in an organism or damage to organic material. The method inhibits bacterial growth in the organism without harming the organism or other organisms in the environment. The method includes formulating an antimicrobial agent that is taken up to the vector organism known to spread disease due to the presence of harmful microbes such as bacteria living in the organism. The antimicrobial agent eradicates and/or inhibits the future growth of the bacteria in the organism, thereby leaving the organism free of the infecting bacteria while not being a poison to the organism.

Abstract: Some embodiments of a system or method for applying a barrier composition to a targeted skin surface can be used to as a preventative measure to reduce the likelihood of transmission of microbial entities from an external source (e.g., a floor surface or another surface) to the targeted skin surface.

Abstract: The invention is a method of exterminating a harmful insect with an agricultural and horticultural insecticide containing one or more kinds of compound (A) selected from a specific polyoxyethylene fatty acid ester, a specific polyoxyethylene sorbitan fatty acid ester, a specific (poly)glycerol fatty acid ester, and a specific alkyl saccharide, and a compound (B) of an alcohol having a linear or branched alkyl group having 8 to 14 carbon atoms or a linear or branched alkyl ether having 6 to 12 carbon atoms, provided that an agricultural chemical ingredient of an agricultural chemical is not substantially contained.

Abstract: Mixture of fatty acids, their derivatives, ester or methyl ester derivates thereof, which may be administered to non-human mammals by diffusion in to ambient air during at least seven consecutive days, with a rapid kinetic of diffusion during the first three days of administration.

Abstract: Cationic surfactants derived from the condensation of fatty acids and esterified dibasic amino acids, such as from lauric acid and arginine, in particular the ethyl ester of the lauramide of the arginine monohydrochloride (LAE), may be used for the treatment of objects which are infected with spores. The spores may originate from bacteria or fungi.

Abstract: An anti-inflammatory composition for treatment of inflamed joints. This composition includes an alkali buffered creatine and a cetylated fatty acid. The composition can be used for treating inflammation either by oral ingestion or by topical treatment.

Abstract: [Problem] To provide a novel antimicrobial agent that has excellent antimicrobial activity and which is prepared from an ester composed of propanediol and a ?-hydroxycarboxylic acid. [Solution] An antimicrobial agent which is prepared from a propanediol mono-?-hydroxycarboxylic acid ester expressed by the following formula (1) or formula (2) (wherein R1 and R2 are both branched or unbranched, and saturated or unsaturated alkyl groups having 5 to 9 carbon atoms).

Abstract: The invention relates to an inhibitor of dimethylarginine dimethylaminohydrolase (DDAH) of general structural formula (I), wherein B is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromatic system having a ring size of 3 to 6; R1 is selected from the group of structures (i-vii), wherein R2, R3 and R4 are selected from the group consisting of hydrogen, an alkyl or aryl radical, R5 and R6 are selected from the group consisting of hydrogen, a hydrocarbon chain having a chain length of 1 to 8 and an aryl radical, R7, R8, R9 and R10 are selected from the group consisting of hydrogen, and alkyl or aryl radical; W is oxygen (O) or nitrogen (N); and X is a methylene group (CH2) or a secondary amino group (NH); Y is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromat

Abstract: The present invention relates to the identification of provided cyclohexane-1,3-diones (CHD compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided CHD compounds.

Abstract: The present invention relates to a composition including at least one C7 sugar, or derivative from esterification of said sugar, and a pharmaceutically acceptable carrier for treating alopecia. The present invention also relates to a method for cosmetically treating hair and nails, said method being intended to stimulate the growth thereof and/or slow the loss thereof. According to said method, a cosmetic composition including at least one C7 sugar, or derivative from esterification of said sugar, is administered. The present invention finally relates to a method for cosmetic care of hair and/or eyelashes and/or nails.

Abstract: A synergistic composition, or the use of that composition in the manufacture of a medicament, or a method of treatment including the use of that composition, for the treatment of hair loss and baldness, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists, in the form of a lotion: 1600-2400 IU/mL Vitamin A Palmitate, 0.64%-0.96% Thiamine Hydrochloride, 0.64%-0.96% Pyridoxine Hydrochloride, 4.8%-7.2% Niacinamide, 2.85%-5.2% D-Panthenol, 1.6%-2.4% L-Arginine, 3.6%-4.4% Methyl Sulphonyl Methane (MSM), 0.08%-0.12% Ginger Oil, 0.08%-0.12% Cinnamon Oil, 0.0996%-0.1494% Oleoresin Capsicum, 1.3%-1.95% Magnesium, 2.4%-3.6% Zinc, 0.192%-0.288% Manganese, 2.6%-3.9% Urea, 2.4%-3.6% Sodium Glycerophosphate, 4.8%-7.2% L-Lysine HCl, plus Preservatives, Co-solvent (Propylene Glycol), Fragrances, Anti-Oxidant, Cooling agent (Menthol), Emulsifier, and Vehicle (Purified water).

Abstract: An antimicrobial composition and method for extending the shelf-life of water, food/feed or food/feed ingredients, comprising: 5-25 wt. % nonanoic acid, 1-25 wt. % organic acid ester, 1-50 wt. % of a single or mixture of C1-C24 aldehydes, a mixture of C1-C24 organic acids, and water.